Advertisement

Topics

Popular Biotech News, Healthcare News and Pharma News

02:30 EST 21st February 2017 | BioPortfolio

FDA approves Gilead’s Odefsy for treatment of HIV-1 infection

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has approved its TAF-based single tablet regimen Odefsey (emtricitabine, rilpivirine and tenofovir alafenamide) for the treatment of HIV-1 infection in certain patients. read more

MannKind Corp MNKD Financial and Strategic SWOT Analysis Review [Updated: 08022017] Prices from USD $125

MannKind Corp MNKD Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your bu...

Proof of Concept Studies confirm RPL554 delivery possible via industry-standard inhaler devices

Verona Pharma plc (‘Verona’ or the ‘Company’) 26 November 2010 – Verona Pharma plc (AIM: VRP), the biotechnology company focused on the research, discovery and development of new therapeutic drugs for the treatment of chronic respiratory diseases, has completed proof of concept experimental studies showing that its lead drug compound, RPL554, can be delivered ...

Otrivine Mu-Cron discontinued

Novartis has discontinued Otrivine Mu-Cron (paracetamol, pseudoephedrine hydrochloride) with immediate effect.

Dr. Kayla Gertsema Joins Eating Recovery Center, Austin

Leading child and adolescent psychiatrist brings steadfast commitment to add comprehensive care to the Austin-based eating disorder treatment center Austin, TX (PRWEB) October 26, 2016 Eating Recovery Center, Austin (ERC Austin), a trusted provider of comprehensive treatment for eating disorders, announced today the addition of Dr. Kayla Gertsema to its clinical leadership team. Dr. Gertsema will...

Dental Instrument and Appliance Market in Egypt to 2020 Market Size, Development, and Forecasts Prices from USD $540

The report Dental Instrument and Appliance Market in Egypt to 2020 Market Size, Development, and Forecasts offers the most uptodate industry data on the actual market situation, and future outlook for dental instruments and appliances in Egypt. The research includes historic data from 2009 to 2015 and forecasts until 2020 which makes the report an invaluable resource for industry executives, mark...

Milk Dairy and Soy Food Market in Czech Republic Outlook to 2020: Market Size, Growth and Forecast Analytics Prices from USD $750

SummaryMilk all types of dairy milk including flavoured and unflavoured milks, long life / uht milk, condensed milk and buttermilks. Includes milkshake drinks. However, excludes soy and rice milks and yoghurt based smoothie/"thickie" drinks.Milk Dairy and Soy Food Market in Czech Republic Outlook to 2020: Market Size, Growth and Forecast Analytics is a broad level market review of Milk market of...

Mitotech S.A. Developing a Dry Eye Treatment has been Granted Two U.S. Patents for Pharmaceutical Formulations

Mitotech S.A., a Luxembourg based clinical stage biotechnology company developing a Dry Eye treatment announces issuance of two U.S. patents for pharmaceutical formulations of its lead compound SkQ1 Luxembourg (PRWEB) January 05, 2017 Mitotech S.A., a Luxembourg based clinical stage biotechnology company focused on developing treatments for age-related disorders such as Dry Eye Syndrome, announce...

Virbac : annual sales growth of 4.5%, at constant exchange rates

Virbac: annual sales growth of 4.5%, at constant exchange rates Public release - January 17th, 2017 Virbac consolidated revenue in the fourth quarter reached 225.7 M€, a significant +9.2% growth compared to the same period of last year and a +8.6% increase at constant scope. Growth was driven primarily by sales in the United States of historical ranges, including internal par...

Achtung! Diese Aktien sind aktuell im Visier der Leerverkäufer - Lanxess, K+S, Deutsche EuroShop, Leoni, Qiagen, Pfeiffer Vacuum, Heideldruck

Liebe Leser, hier finden Sie einen Überblick über die aktuellen Veränderungen bei den Leerverkaufspositionen deutscher Aktien am 18. Januar. Seit geraumer Zeit sind die Aktien deutscher Unternehmen...

Nova Oculus Recruits Emergo to Assist with Global Compliance

Job One is to help achieve regulatory approvals in Canada Indian Wells, CA (PRWEB) January 21, 2017 Nova Oculus Partners has forged another key alliance in our ongoing endeavors to bring to market a pioneering medical device for the treatment of Age-Related Macular Degeneration. The company’s chief operating officer, Walter O’Rourke, has signed an engagement contract with Emergo, a global reg...

Merck KGaA, Domain to Develop Adenosine Receptor Inhibitors for Immuno-Oncology

Merck KGaA will support research and gain global rights to Domain Therapeutics’ next generation of adenosine receptor inhibitors, through a collaboration designed to develop the compounds as novel immuno-oncology agents. The value of the collaboration and licensing agreement was not disclosed. Adenosine receptor antagonists are small molecules that are believed to slow tumor progression ...

Five Dermatology Trends Expected to Be Huge in 2017

Dr. Melda Isaac, board-certified dermatologist and founder of MI Skin Dermatology Center in Washington, DC, discusses dermatological treatments predicted to be big in 2017. Washington, DC (PRWEB) February 01, 2017 In the past decade, platelet-rich plasma (PRP) treatments have become common in orthopedics, but you may soon enjoy more benefits of this innovative treatment on your skin. According to...

CPhI Worldwide experts make pharma predictions for 2017: the good, the bad, and the Donald

Orphan drugs, CMO continuous manufacturing and developing world sales offer the biggest revenue opportunities in pharma. The post CPhI Worldwide experts make pharma predictions for 2017: the good, the bad, and the Donald appeared first on PharmaAsia.

Portola Pharma assigns AndexXa royalties to HealthCare Royalty Partners

Portola Pharmaceuticals has sold the royalty rights to AndexXa (andexanet alfa) to HealthCare Royalty Partners (HCR) for up to $150m.

Role of NAD+ and mitochondrial sirtuins in cardiac and renal diseases

Nicotinamide adenine dinucleotide (NAD+) depletion contributes to the pathogenesis of cardiac and renal diseases. Here, the authors review the roles of NAD+ in the heart and kidney and discuss the mechanisms by which NAD+ supplementation might have therapeutic efficacy, with a focus on the role of mitochondrial sirtuins.

α-Lipoic acid treatment prevents cystine urolithiasis in a mouse model of cystinuria

Excess urinary cystine can lead to painful stone formation. There is no current effective treatment, but here Pankaj Kapahi, Marshall Stoller and colleagues have found that α-lipoic acid can prevent or even reverse formation of these stones in a mouse model.

BlueCross Continues Rapid Growth in Medicare Advantage Business

BlueCross BlueShield of Tennessee’s Medicare Advantage (MA) line of business had the largest growth among MA carriers in the state, gaining almost 11,000 members during the recent annual enrollment period. The BlueCross Medicare Advantage Plan grew 10.5 percent with 10,499 new members for a total enrollment of 110,657. Including both Medicare Ad...

Personalized Treatment with Erbitux in Head and Neck Cancer Promising

Researchers from UCLA have reported that a short course of the drug Erbitux® (cetuximab) in combination with standard chemotherapy and radiation improves survival in individuals diagnosed with advanced head and neck squamous cell carcinoma and the KRAS genetic mutation. Head and neck cancers originate in the throat, larynx (voice box), pharynx, salivary glands, or oral […] The post Personal...

Terumo buys Bolton Medical

Terumo Corp. is acquiring Bolton Medical Inc. from WerfenLife Group SA for an undisclosed sum, which Terumo will fund with cash and debt.

Preventing hospital-related deaths due to medical errors—'We can and must do better'

How many patients die in the hospital as a result of preventable medical errors? While debate continues over estimates based on flawed data, the US healthcare system can and must implement effective strategies to reduce adverse events and deaths, according to a special perspective article in the March Journal of Patient Safety.

IBB: Merck Joins The Drug Pricing Coalition For Transparency

Trump stated that drug companies are "getting away with murder" when speaking to the drug pricing issue that has taken the spotlight. Many large-cap pharma companies have created a drug pricing coalition to reign in transparency and separate themselves from the few bad actors.

No Drugs for Back Pain, New Guidelines Say

The American College of Physicians says back pain of all kinds should be treated with natural and alternative therapies, such as exercise, acupuncture and mindfulness.

As Tom Price Takes Over HHS, Studies Back Accountable Care Organizations

Accountable care organizations (ACOs) are getting favorable reviews as a way to reduce costs and improve health quality for Medicaid and Medicare patients in two new studies in JAMA Internal Medicine.

Peak, the Brain Training App, Launches Memory Training Masterclass with 4X USA Memory Champ Nelson Dellis To Boost Memory Skills

Learn the memory hacks and techniques that have made Dellis a leading memory athlete to better recall multiple passwords, lists and facts, names and faces and more - all in one fun app. London, UK (PRWEB) February 14, 2017 Peak, the award-winning brain training app, is proud to announce today that its latest module “Memory Masterclass,” created with Nelson Dellis, the 4-time USA Memory Champi...

Acadia Pharmaceuticals Inc ACAD Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250

SummaryAcadia Pharmaceuticals Inc Acadia is a biopharmaceutical company, which focuses on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Acadia's lead product is Nuplazid pimavanserin is a FDA approved drug for the treatment of Parkinson's disease psychosis. Its other pipeline products include pimavanserin for the tre...

Rhizen Pharmaceuticals SA Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250

SummaryRhizen Pharmaceuticals SA Rhizen Pharma is a biopharmaceutical company that focuses on discovery and development of small molecule drugs for the treatment of cancer, autoimmune diseases, inflammation and metabolic disorders. Its product portfolio includes selective CMet inhibitors, selective P13K inhibitors, CRAC channel inhibitors and GPR 119 agonist. The company conducts research in the t...

Researchers find new treatment to reverse COPD, other lung diseases

In a study conducted on mice, researchers found a receptor that could reverse inflammatory responses and combat chronic obstructive pulmonary disease (COPD) and other lung diseases.

Innovacell Biotechnologie AG Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250

SummaryInnovacell Biotechnologie AG Innovacell is a biotechnology company that develops therapeutic products. The company provides personalized cell therapy products for the treatment of incontinence. It offers personalized medical products that includes ICES13 and ICEF15. Innovacell's products are used in the treatment of stress urinary incontinence and faecal incontinence. The company provides a...

Celgene’s Multiple Sclerosis Pill Meets Primary Endpoint in First Late-Stage Clinical Trial

SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ: CELG) today announced that its phase III SUNBEAM trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (ARR), compared to weekly interferon (IFN) β...

Perrigo Partnering Deals and Alliances 2010 to 2017 [Updated: 01022017] Prices from USD $1495

The Partnering Deals and Alliance since 2010 report provides an indepth insight into the partnering activity of one of the world's leading life sciences companies.On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data. The report will be delivered in PDF format within 1 working day of receipt of order. If the CDRom version purchased, t...

BMT Tandem Meetings on Blood & Marrow Transplantation to be Held in Orlando

The BMT Tandem Meetings of the American Society for Blood and Marrow Transplantation (ASBMT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) will take place Feb. 22-26, 2017 at the Gaylord Palms Convention Center in Orlando, Fla. Arlington Heights, IL (PRWEB) February 17, 2017 The BMT Tandem Meetings of the American Society for Blood and Marrow Transplantation (AS...

Zafgen Inc ZFGN Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300

SummaryZafgen Inc Zafgen is a biopharmaceutical company that develops therapeutics for patients suffering from obesity and related disorders. The company's product beloranib is a novel obesity therapy provided for obesity patients. It concentrates on targeting fat tissue to treat obesity. The company's pipeline products include, beloranib, ZGN839 and MetAP2i. Zafgen's obesity treatments include we...

Darunavir Linked to Heightened Heart Disease Risk

The early protease inhibitors are known to increase risk for heart attack, stroke, and sudden cardiac death. Now, data from the D:A:D study raise concerns about next-generation drugs. Medscape Medical News

News digest – landmark week for CRISPR genome editing, cancer-preventing drugs, lifetime weight and…‘manageable’ pancreatic cancer?

A big week for CRISPR genome editing, GPs need support on cancer-preventing drugs and can this ‘treatment’ really make pancreatic cancer manageable?

Meiji Seika Pharma Co Ltd Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250

SummaryMeiji Seika Pharma Co Ltd Meiji Seika Pharma, a subsidiary of Meiji Holdings Co Ltd is a pharmaceutical company that develops, manufactures and markets ethical pharmaceuticals, agricultural chemicals and veterinary drugs. The company offers products including udenafil, mirtazapine, fluvoxamine, ziprasidone, and others. It provides research and development programs on infectious diseases and...

Biocept Inc BIOC Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300

SummaryBiocept Inc Biocept is a medical equipment company that provides diagnostics services. The company provides biopharmaceutical and clinical research, and molecular oncology laboratory services. It provides tests for various solid tumor cancers. Biocept offers OncoCEE technology, related instrumentation and analytical capabilities for rare event detection and genetic characterization. The com...

Cardinal Capital Management Buys Novo Nordisk A/S, Envision Healthcare, Rocky Mountain ...

Raleigh, NC, based Investment company Cardinal Capital Management buys Novo Nordisk A/S, Envision Healthcare, Rocky Mountain Chocolate Factory, Boston Beer Co, Under Armour, Sonic, sells Teva Pharmaceutical Industries, Tompkins Financial, Under Armour during the 3-months ended 2016-12-31, according to the most recent filings of the investment company, Cardinal Capital Management. As of 2016-12-31,...

Surgical Care Affiliates LLC SCAI Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300

SummarySurgical Care Affiliates LLC SCA is a healthcare organization that offers patient care services. The organization's services include physician governance and engagement, scheduling optimization, staffing optimization, supply chain optimization, and case costing and profitability analysis. It offers patient safety, clinical training, regulatory preparedness and survey readiness programs. SCA...

Humana Inc. Strategy, SWOT and Corporate Finance Report Prices from USD $175

SummaryHumana Inc. Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360 view of the company.Key Findings Detailed information on Humana Inc. required for business and competitor intelligence needs A study of th...

The battle for CRISPR/Cas9 gene-editing technology: what patent applicants need to know

CRISPR provides researchers with an easily accessible technique for making highly specific changes to DNA in viable cells. Interest in this gene-editing technique has been driven by its ease of use, potential for relative low cost and speed of implementation. Indeed, this technique is considered so easily accessible that it has recently been reported that ‘biohackers’ (hobbyists often with no ...

The show goes on: Trump attends controversial Dana-Farber fundraiser at Mar-a-Lago

President Trump attended the fundraiser for Dana-Farber Cancer Institute, held at Mar-a-Lago — his Florida home and so-called winter White House.

Kopran Ltd KOPRAN Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300

SummaryKopran Ltd Kopran is a pharmaceutical company that provides finished dosage forms, consumer healthcare products and active pharmaceutical ingredients. The company's finished dosage form products include tablets, dry powders for oral suspension, capsules, injections and syrups. Its finished dosage forms are used for anthelmintic, anti allergic, antibiotic, anti fungal, pain management, anti ...

OpGen Inc OPGN Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300

SummaryOpGen Inc OpGen is a biotechnology company that offers tools for genomic sequence assembly and finishing, microbial strain comparison and species characterization. The company offers products which include argus system and consumables. It offers MDRO and genomic services. OpGen's pipeline products comprise Acuitas Lighthouse MDRO Management System and the Acuitas Resistome Test. Its Genomic...

Aurinia Pharmaceuticals Inc AUP Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300

SummaryAurinia Pharmaceuticals Inc Aurinia Pharmaceuticals focuses on the development and commercialization of therapies for the treatment of autoimmune diseases. The company's lead product candidate includes voclosporin, a novel therapeutic immunomodulating differentiated calcineurin inhibitor that is used for the treatment of lupus nephritis, an inflammation of the kidney caused by systemic lupu...

DBV Technologies SA DBV Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300

SummaryDBV Technologies SA DBV is a biopharmaceutical company that develops products for the diagnosis and treatment of food and pediatric allergies. The company develops and markets noninvasive epicutaneous delivery technology and products for healthcare markets. Its technology platform Viaskin, is an electrostatic patch that provides a suitable, selfadministered and noninvasive immunotherapy to ...

ProMetic Life Sciences Inc PLI Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300

SummaryProMetic Life Sciences Inc ProMetic is a biopharmaceutical company that focuses on bioseparations, plasmaderived therapeutics, and smallmolecule drug development. The company develops products for various areas such as fibrosis, anemia, autoimmune diseases, inflammation, and nephropathies. It operates through its segments including protein technologies and therapeutics. ProMetic's protein t...

Centauri Therapeutics Ltd closes £2.5m fundraising

Second tranche of seed financing secured, sufficient to develop first lead candidate through to proof of principle £1.2m raised in oversubscribed completion of funding round London and Kent, UK, 20th February 2017: Centauri Therapeutics Ltd, a biotechnology company focused on the treatment of infectious diseases and cancer, announced today that it has secured an additional £...

Quick Search
Advertisement